Gumetinib does not belong to the traditional "first generation" or "third generation" targeted drug generation system, and it is usually not classified in this way. The traditional intergenerational division mainly focuses on drugs targeting EGFR, ALK, and other targets, while Gu Mei Ti Ni is a highly selective MET inhibitor and belongs to the national Class 1 innovative drug. We are more concerned about its precise ability to target specific gene mutations, rather than being fixated on the generation.
1、 The reason why the traditional "intergenerational"
division does not apply to the "first, second, and third generations" of targeted drugs is mainly due to the iterative history of drugs targeting EGFR, ALK, etc., which is usually related to the chronological order of solving resistance problems.
Examples of EGFR targeted drugs include first generation drugs such as gefitinib and third generation drugs such as osimertinib, which were mainly developed to address specific drug-resistant mutations (such as T790M).
Characteristics of MET inhibitors: Metformib, a type of MET targeted drug, was developed with the aim of precisely targeting specific abnormalities in the MET gene, such as MET 14 exon skipping mutations or amplifications. Its design concept is "high selectivity" and "overcoming drug resistance", rather than a simple linear upgrade relationship.
2、 The practical role and advantages of Gu Mei Ti Ni lie in its precise and potent mechanism of action, which is reflected in the following aspects:
Precision inhibition: As an oral, potent, and highly selective small molecule MET inhibitor, it can precisely block tumor cell growth and proliferation signals driven by MET gene abnormalities, reducing interference with unrelated targets.
Overcoming drug resistance: For patients who develop MET amplification as a resistance mechanism after using other targeted drugs (such as EGFR inhibitors), glutatinib can effectively respond and provide opportunities for subsequent treatment.
Control brain metastasis: Clinical trials have shown that gefitinib is not only effective against tumors throughout the body, but also demonstrates good control ability against brain metastases.
